VBI Vaccines Inc. (NASDAQ:VBIV) has a beta value of 0 and has seen 10,423,129 shares traded in the last trading session. The company, currently valued at $813.82 Million, closed the last trade at $3.52 per share which meant it gained $0.4 on the day or 12.82% during that session. The VBIV stock price is -96.88% off its 52-week high price of $6.93 and 86.78% above the 52-week low of $0.4655. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.77 Million shares traded. The 3-month trading volume is 15.24 Million shares.
The consensus among analysts is that VBI Vaccines Inc. (VBIV) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.22.
VBI Vaccines Inc. (NASDAQ:VBIV) trade information
Sporting 12.82% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Sep 14 when the VBIV stock price touched $3.63-3 or saw a rise of 3.03%. Year-to-date, VBI Vaccines Inc. shares have moved 155.07%, while the 5-day performance has seen it change 6.02%. Over the past 30 days, the shares of VBI Vaccines Inc. (NASDAQ:VBIV) have changed -3.3%. Short interest in the company has seen 15.95 Million shares shorted with days to cover at 1.05.
Wall Street analysts have a consensus price target for the stock at $6.75, which means that the shares’ value could jump 91.76% from current levels. The projected low price target is $3 while the price target rests at a high of $9. In that case, then, we find that the current price level is +155.68% off the targeted high while a plunge would see the stock lose -14.77% from current levels.
VBI Vaccines Inc. (VBIV) estimates and forecasts
Figures show that VBI Vaccines Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +381.73% over the past 6 months, with this year growth rate of -56.52%, compared to 13.6% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 8.3% and -5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +4%.
1 analysts offering their estimates for the company have set an average revenue estimate of $200Million for the current quarter. 1 have an estimated revenue figure of $200Million for the next quarter concluding in December 01, 2018. Year-ago sales stood $193Million and $201Million respectively for this quarter and the next, and analysts expect sales will grow by 3.6% for the current quarter and -0.5% for the next.
Over the next 5 years, the company’s earnings are expected to increase by 0%.